Empaglif M 12.5/500 is used in adults with type 2 diabetes mellitus to help control elevated blood glucose levels. It should be used together with dietary management and physical activity as advised by a healthcare professional.
১০০% অরিজিনাল পণ্যের নিশ্চয়তা
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Empaglif M 12.5/500 is a combination medicine containing empagliflozin 12.5 mg and metformin hydrochloride 500 mg. Empagliflozin belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, while metformin is a biguanide antidiabetic medicine.
It is used along with a suitable diet and regular exercise to improve blood glucose control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is considered appropriate.
Together, these actions help reduce blood glucose levels.
Empaglif M 12.5/500 should not be used in patients with:
Patients with severe acute illness, significant dehydration, or certain serious hepatic or cardiac conditions may require special assessment before treatment.
Take this medicine exactly according to your doctor's prescribed dose and duration. It should generally be taken with meals to reduce the risk of stomach-related side effects associated with metformin.
Swallow the tablet whole with water. Do not chew, crush, or break the tablet unless specifically instructed by your doctor.
The dosage may be adjusted gradually according to blood glucose response and tolerability.
The usual initial dose of the empagliflozin/metformin combination may be 5 mg/500 mg once daily, depending on the patient's previous treatment and clinical condition. The dose can be adjusted by the doctor as required.
The maximum recommended daily amounts are:
Some formulations may be prescribed twice daily with meals. The exact regimen should be determined by the treating physician.
The safety and effectiveness of empagliflozin/metformin combination therapy in individuals under 18 years of age have not been established. Use in children should only be considered when specifically prescribed by a qualified healthcare professional.
Kidney function should be assessed before starting treatment and monitored periodically during therapy.
Use of empagliflozin/metformin may be inappropriate or contraindicated at significantly reduced kidney function. The exact eGFR threshold depends on the formulation and prescribing information; therefore, patients with impaired renal function should use this medicine only under medical supervision.
Pregnancy: Empagliflozin is generally not recommended during pregnancy, particularly during the second and third trimesters, because of potential risks to the developing fetus. Inform your doctor if you are pregnant, planning pregnancy, or become pregnant during treatment.
Breastfeeding: Empagliflozin may pass into breast milk and could potentially affect a breastfed infant. Metformin is also present in breast milk. Your doctor will determine whether breastfeeding should be continued or an alternative treatment should be used.
Take the missed dose when you remember, unless it is almost time for your next scheduled dose. If the next dose is due soon, skip the missed dose and continue with your regular schedule.
Do not take two doses together to make up for a missed dose.
Maintain adequate fluid intake unless your doctor has advised you to restrict fluids.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.